Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances; generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.

Sun Pharmaceutical Industries Limited

Sun Pharma CRAMS

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 2,000 scientists and R&D investments of over 7-8% of annual revenues.

See our community guideline: bit.ly/3DsQxdK

Zenotech Laboratories

Krystal Biotech

scPharmaceuticals

SUN PHARMA

Presenting Cristinela’s inspiring journey of two decades, a true testament to Sun’s culture of inclusivity and empowerment. Her transition from a medical representative to an area business manager, showcases the power of support and collaboration at any age. Here's to breaking barriers and building strong teams together! 

#WomenInPharma #WomenOfSun #SunForAll

Our Global Clinical Operations team recently convened in the vibrant city of Agra, India. It was a dynamic gathering uniting cross-functional experts from India, Japan, and the USA. Together, we explored innovative strategies and insights aimed at achieving excellence in clinical operations.

Anirban Roy Chowdhury Valentina Curovic-Perisic
 
#WeAreSun

As a part of our 'Recycle to Rekindle' initiative led by employee volunteers, we repurposed old and damaged clothing into textiles for the underprivileged. Over a 10-day drive at our Mumbai offices, we collected more than 770 kgs of clothing. These clothing were transformed into beautiful rugs and distributed among specially-abled children, tribal schools, underprivileged communities and senior citizens in remote villages across Maharashtra.

At Sun, we remain dedicated to continuing our commitment to environmental conservation and supporting underprivileged communities. 

#ReachingPeopleTouchingLives #WeAreSun

Sun Pharma wishes everyone a vibrant and joyous Holi!

#Holi2024 #HappyHoli #SunPharma

For Sun, it has been 40 years of Reaching People and Touching Lives. Building a global network one step at a time, we are currently providing high-quality medicines trusted by healthcare professionals and patients in more than 100 countries. With a dedicated team of over 41,000 employees across six continents, we are driven by our core values of quality, reliability, innovation, trust, and consistency. 

#WeAreSun #ReachingPeopleTouchingLives  #40UnderTheSun

Our recently concluded Global Marketing Meet 2024 for the Emerging Markets was a vibrant event that brought together marketing team members from 16 countries across Latin America, Africa, Middle East, and Asia Pacific regions. 

Spread over five days, this diverse gathering served to stimulate innovation and excellence, fostering the exchange of ideas, insights, and collaboration among the attendees! 

#WeAreSun

NSE:SUNPHARMA

Sun Pharmaceutical Industries Ltd.

Last Close

1,836.00

19/09 06:20

Market Cap

3.80T

Beta: 0.39

Volume Today

571.33K

Avg: 2.06M

PE Ratio

39.50

PFCF: -

Dividend Yield

0.79%

Payout:0%